[][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59538]], camposKey:1351-8216 2021-05-01 Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system479487, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59539]], camposKey:1723-2007 2021-01-01 Autologous serum eye drops improve tear production, both lachrymal flow and stability tests and conjunctival impression cytology with transfer in dry eye disease4553, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59540]], camposKey:1351-8216 2020-11-01 Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary9991008, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59541]], camposKey:0340-6245 2020-03-01 Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort437448, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=52143]], camposKey:0902-4441 2020-01-01 Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia259270, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59542]], camposKey:0390-6078 2019-02-28 Unraveling the effect of silent, intronic and missense mutations on VWF splicing: Contribution of next generation sequencing in the study of mRNA587598, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47733]], camposKey:1351-8216 2019-01-01 Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score144153, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47734]], camposKey:0019-9567 2018-01-01 Polymorphisms in receptors involved in opsonic and nonopsonic phagocytosis, and correlation with risk of infection in oncohematology patients00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47737]], camposKey:0007-1048 2017-09-01 Use of eltrombopag for secondary immune thrombocytopenia in clinical practice959970, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47738]], camposKey:0340-6245 2017-01-01 Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes6674, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47736]], camposKey:0925-5710 2017-01-01 Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice508516, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47735]], camposKey:0390-6078 2017-01-01 Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients20052014, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54892]], camposKey:0210-6523 2017-01-01 Proyecto de planificación estratégica para la "Real Academia de Medicina y Cirugía de Valladolid¿8398, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47739]], camposKey:0902-4441 2016-09-01 Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice297302, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47740]], camposKey:1351-8216 2016-07-01 Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders590597, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47741]], camposKey:0939-5555 2016-05-01 Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial893899, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47742]], camposKey:0001-5792 2016-01-01 Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients7684, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47743]], camposKey:0340-6245 2016-01-01 Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm4050, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39232]], camposKey:0006-2952 2016-01-01 Pharmacological inhibition of eicosanoids and platelet-activating factor signaling impairs zymosan-induced release of IL-23 by dendritic cells7896, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44675]], camposKey:0210-6523 2015-01-01 Enfermedad de Gaucher125142, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47745]], camposKey:0361-8609 2015-01-01 Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47744]], camposKey:0007-1048 2015-01-01 Use of eltrombopag after romiplostim in primary immune thrombocytopenia111116, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44677]], camposKey:0210-6523 2014-01-01 Presente y futuro del tratamiento anticoagulante oral113128, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=39233]], camposKey:0021-9258 2014-01-01 The Unfolded Protein Response and the Phosphorylations of Activating Transcription Factor 2 in the trans-Activation of il23a Promoter Produced by beta-Glucans2294222957, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47746]], camposKey:0902-4441 2013-09-01 Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia236241, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=43889]], camposKey:0210-6523 2013-01-01 Situación actual de los nuevos anticoagulantes orales99112, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=30382]], camposKey:0105-4538 2012-01-01 Thrombosis after anaphylaxis to seeds: a Kounis syndrome variant?518518, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=12779]], camposKey:0301-0546 2011-01-01 Food anaphylaxis in antiphospholipid syndrome and thrombosis212221, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=12778]], camposKey:0301-0546 2011-01-01 The association of food anaphylaxis in antiphospholipid syndrome and thrombosis cannot be considered a coincidence3140, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47712]], camposKey:0002-8703 2010-01-01 Absence of accelerated atherosclerotic disease progression after intracoronary infusion of bone marrow derived mononuclear cells in patients with acute myocardial infarction-Angiographic and intravascular ultrasound-Results from the TErapia Celular Aplicada al Miocardio Pilot study00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=30478]], camposKey:0105-4538 2010-01-01 Anaphylaxis to vegetables in patients with antiphospolipid antibodies and thrombosis586587, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47748]], camposKey:0390-6078 2010-01-01 Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study19131920, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44676]], camposKey:0210-6523 2010-01-01 La cirugía en el paciente con hemofilia6584, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47749]], camposKey:0002-9149 2009-06-15 Comparison of Neointimal Hyperplasia With Drug-Eluting Stents Versus Bare Metal Stents in Patients Undergoing Intracoronary Bone-Marrow Mononuclear Cell Transplantation Following Acute Myocardial Infarction16511656, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47750]], camposKey:0145-2126 2009-06-01 Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47751]], camposKey:0732-183X 2008-12-10 Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival57755782, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47752]], camposKey:0006-4971 2008-11-01 A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma35913593, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47810]], camposKey:0300-8932 2008-01-01 Effect of persistent microvascular obstruction on post-infarction ventricular remodeling following intracoronary bone-marrow cell transplantation: A contrast-enhanced cardiac magnetic resonance study Impacto de la obstrucción microvascular persistente en el remodelado ventricular postinfarto tras el implante intracoronario de células mononucleadas de médula ósea: Un estudio de cardiorresonancia602610, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22429]], camposKey:0210-6523 2008-01-01 Nuevas perspectivas en el tratamiento y curación de las leucemias275288, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44262]], camposKey:0210-6523 2008-01-01 Tratamiento con anticoagulantes orales: dilemas y soluciones7184, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47753]], camposKey:0929-5305 2006-01-01 Oral anticoagulant treatment: Risk factors involved in 500 intracranial hemorrhages113120, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47754]], camposKey:1351-8216 2005-11-01 Psychometric field study of the new haemophilia quality of life questionnaire for adults: The 'Hemofilia-QoL'603610, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47755]], camposKey:1130-0108 2005-09-01 Primary biliary cirrhosis, "sicca" syndrome and autoimmune hemolytic anemia [5] Cirrosis biliar primaria, síndrome "sicca" y anemia hemolítica autoinmune678679, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44679]], camposKey:0210-6523 2005-01-01 Terapia regenerativa celular mediante células madre adultas de médula ósea187201, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=22428]], camposKey:0210-6523 2005-01-01 Tratamiento del mieloma múltiple con trasplante autólogo de progenitores hematopoyéticos93109, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47756]], camposKey:1466-4860 2004-12-01 Bone remodelation markers are useful in the management of monoclonal gammopathies480488, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47757]], camposKey:1351-8216 2004-01-01 Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia376382, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=38347]], camposKey:0009-7330 2004-01-01 Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction742748, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47713]], camposKey:0300-8932 2004-01-01 Intracoronary stem cell transplantation in acute myocardial infarction Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio201208, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=14434]], camposKey:0300-8932 2004-01-01 Regeneración miocárdica mediante la implantación intracoronaria de células madre en el infarto agudo de miocardio201208, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44263]], camposKey:0210-6523 2004-01-01 Trombosis venosa en pacientes con factor V Leiden4959, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47758]], camposKey:1466-4860 2003-08-11 Emphysematous gastritis and severe aplastic anemia8284, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47759]], camposKey:0014-2565 2003-05-01 Treatment of coagulopathy in severe sepsis Tratamiento de la coagulopatía en la sepsis severa240241, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47760]], camposKey:0093-7754 2003-01-01 Immunophenotypic analysis of Waldenstrom's macroglobulinemia187195, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44261]], camposKey:0014-2565 2003-01-01 Tratamiento de la coagulopatía en la sepsis severa240241, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=41290]], camposKey:0014-2565 2002-01-01 Dyspnea, cough, and pulmonary mass405406, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47761]], camposKey:0049-3848 1998-01-15 Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma5964, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=44674]], camposKey:0210-6523 1997-01-01 Aspectos clínicos de la fibrinolisis5158, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47762]], camposKey:0268-9499 1996-01-01 Markers of coagulation and fibrinolysis in burned patients and its relation to outcome 1 Gª00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=59543]], camposKey:0268-9499 1996-01-01 Markers of coagulation and fibrinolysis in burned patients and its relation to outcome 1 Ga00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47763]], camposKey:0025-7931 1995-01-01 Efficacy of D-dimer and total fibrin degradation products evaluation in suspected pulmonary embolism258262, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47764]], camposKey:0049-3848 1994-09-01 High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis513520, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47765]], camposKey:0036-4355 1994-02-01 Hodgkin's disease following non-Hodgkin's lymphoma Enfermedad de Hodgkin tras linfoma no Hodgkin.00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47766]], camposKey:0049-3848 1994-01-15 High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA109115, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47767]], camposKey:0036-4355 1994-01-01 Familial thrombophilia associated to resistance to activated protein C TROMBOFILIA FAMILAR DEBIDA A RESISTENCIA A LA PROTEINA C ACTIVADA283286, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47768]], camposKey:0036-4355 1994-01-01 Oral anticoagulation control on capillary blood CONTROL DE LA ANTICOAGULACION ORAL EN SANGRE CAPILAR257260, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47769]], camposKey:0036-4355 1993-08-01 Standardization of methods for studying fibrinolysis Estandarización de los métodos de estudio en fibrinolisis.265266, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47770]], camposKey:0014-2565 1993-07-30 Thrombolysis: State of the art. Need of antithrombotic therapy ESTADO ACTUAL DE LA TROMBOLISIS. NECESIDAD DE LA TERAPEUTIFCA ANTITROMBOTICA COADYUVANTE8892, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47771]], camposKey:0036-4355 1993-01-01 Analysis of the fibrinolytic response on disseminated intravascular coagulation Análisis de la respuesta fibrinolítica en la coagulación intravascular diseminada.221224, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47772]], camposKey:0210-5691 1993-01-01 Thromboelastographic evaluation of an experimental septic model VALORACION TROMBOELASTOGRAFICA EN UN MODELO DE SEPSIS EXPERIMENTAL270275, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47773]], camposKey:0012-3692 1993-01-01 Time course of hemostatic abnormalities in sepsis and its relation to outcome15361542, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47774]], camposKey:0210-5691 1992-12-01 Coagulation and fibrinolysis disorders in experimental sepsis ALTERACIONES DE LA COAGULACION Y DE LA FIBRINOLISIS EN LA SEPSIS EXPERIMENTAL387391, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47775]], camposKey:0014-2565 1992-06-01 Hypofibrinolysis in coronary artery disease and predisposing conditions Hipofibrinólisis en enfermedad arterial coronaria y situaciones predisponentes.12, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54893]], camposKey:0001-5792 1992-01-01 A continuous spectrum of hypercoagulability exists in acute nonlymphoblastic leukemia100104, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47777]], camposKey:0210-895X 1992-01-01 Haemorrhagic complications in thrombolytic therapy COMPLICACIONES HEMORRAGICAS EN TERAPEUTICA TROMBOLITICA117125, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47778]], camposKey:0001-5792 1992-01-01 High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia710, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=54894]], camposKey:0361-8609 1992-01-01 Plasminogen activator inhibitor¿1 levels determine the profibrinolytic response in disseminated intravascular coagulation303304, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47776]], camposKey:0036-4355 1992-01-01 Trends for a pathophysiological focusing of the treatment of the consumption coagulopathy in acute non-lymphoblastic leukaemia HACIA UN ENFOQUE FISIOPATOLOGICO DEL TRATAMIENTO DE LA COAGULOPATIA DE CONSUMO EN LA LEUCEMIA AGUDA NO LINFOBLASTICA279282, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47779]], camposKey:0049-3848 1991-08-15 Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease407418, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47780]], camposKey:0140-6736 1991-04-06 Plasma D-dimer in suspected pulmonary embolism00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47784]], camposKey:0014-2565 1991-01-01 Hemostasis profiles in thrombotic disease Perfiles de hemostasia en la enfermedad trombótica.227233, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47786]], camposKey:0001-5792 1991-01-01 Hereditary hemorrhagic telangiectasia: Analysis of platelet aggregation and fibrinolytic system in seven patients119123, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47782]], camposKey:0036-4355 1991-01-01 Lipoprotein-mediated functional changes in the fibrinolytic system in the genesis of atherosclerosis Alteración funcional del sistema fibrinolítico mediada por lipoproteínas en la génesis de aterosclerosis.2528, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47781]], camposKey:0036-4355 1991-01-01 New methods and old concepts in the biological diagnosis of disseminated intravascular coagulation (DIC) Nuevos métodos y viejos conceptos en el diagnóstico biológico de la coagulación intravascular diseminada (CID).117121, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47785]], camposKey:0268-9499 1991-01-01 PAI and D-D dimer levels are related to severity of injury in trauma patients253256, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47787]], camposKey:0268-9499 1991-01-01 Silent myocardial ischaemia episodes in non-insulin dependent diabetes mellitus: relationship with haemostatic alterations121125, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47783]], camposKey:0036-4355 1991-01-01 White thrombus syndrome and low molecular weight heparin SINDROME DEL TROMBO BLANCO Y HEPARINA DE BAJO PESO MOLECULAR327328, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47788]], camposKey:0755-4982 1990-12-01 Value of plasma D-dimers in the diagnosis of pulmonary thromboembolism00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47789]], camposKey:0049-3848 1990-07-01 Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus5159, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47790]], camposKey:0036-4355 1990-01-01 New trends in prophylaxis and therapy of thromboembolic disease: Low molecular weight heparins NUEVAS OPCIONES EN LA PREVENCION Y TRATAMIENTO DE LA ENFERMEDAD TROMBOEMBOLICA: LAS HEPARINAS DE BAJO PESO MOLECULAR389396, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47791]], camposKey:0049-3848 1989-10-01 Thrombus age and tissue plasminogen activator mediated thrombolysis in rats6775, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47792]], camposKey:0014-2565 1989-01-01 Thrombolytic agents: Efficacy related to the evolution time and doses7579, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47793]], camposKey:0014-2565 1988-01-01 Increased fibrinolytic activity in patients with type IV hyperlipoproteinemia treated with bezafibrate151154, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47794]], camposKey:0340-6245 1988-01-01 Investigation by HPLC of the catabolism of recombinant tissue plasminogen activator in the rat107112, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47795]], camposKey:0049-3848 1987-09-01 Changes in fibrinolysis in the intensive care patient593599, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47797]], camposKey:0340-6245 1986-12-01 Bioavailability in rats of human recombinant tissue plasminogen activator after subcutaneous and intramuscular injection299301, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47796]], camposKey:0034-9402 1986-12-01 Purification of fibronectin using gelatin derivatives Purificación de fibronectina mediante derivados de gelatina.535541, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47798]], camposKey:0025-7753 1986-07-16 Fibronectin and plasma ability to induce adhesion and phagocytosis in acute myeloid leukemia FIBRONECTINA Y CAPACIDAD DEL PLASMA DE INDUCIR ADHESION FAGOCITOSIS EN LA LEUCEMIA MIELOIDE AGUDA454456, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47799]], camposKey:0014-2565 1986-03-01 Plasma fibronectin and atherosclerotic processes Fibronectina plasmática y procesos ateroscleróticos.226228, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47800]], camposKey:0036-4355 1985-01-01 Phospholipids and platelet procoagulant activity in myeloproliferative syndromes Fosfolípidos y actividad procoagulante plaquetaria en síndromes mieloproliferativos.2227, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47801]], camposKey:0036-4355 1984-12-01 Homo and heterozygosity in Glanzmann's thrombasthenia Homo y heterozigosidad en trombastenia de Glanzmann.10001007, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47802]], camposKey:0036-4355 1984-01-01 Plasma fibronectin in acute myeloid leukaemia FIBRONECTINA PLASMATICA EN LEUCEMIA MIELOIDE AGUDA376383, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47803]], camposKey:0014-2565 1983-10-31 Optical and ultrastructure study of the effect of Serratia marcescens endotoxin at the hepatic level Estudio óptico y ultraestructural del efecto de la endotoxina de Serratia marcescens a nivel hepático.107110, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47804]], camposKey:0036-4355 1979-12-01 Acquired agranulocytosis - transient or self-maintained - with probable immune pathogenesis. Analysis of 44 cases AGRANULOCITOSIS ADQUIRIDAS -TRANSITORIAS O AUTOPERPETUABLES- DE PROBABLE PATOGENIA INMUNE. ANALISIS DE CUARENTA Y CUATRO CASOS819827, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=47805]], camposKey:0569-9894 1975-01-01 Effects of the oral contraceptives on the pancreatic structure EFECTOS DE LOS ANOVULATORIOS ORALES SOBRE LA ESTRUCTURA PANCREATICA219230][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=17242]},camposKey: 187 201 Autologous mononuclear bone marrow transplantation for myocardial infarction: The Spanish experience 978-0-387-30939-2Stem Cell Therapy and Tissue Engineering for Cardiovascular Repair: From Basic Research to Clinical Applications 1 2006-01-01 Springer US, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=27884]},camposKey: 1049 1056 Estudio de las lesiones hidroelectrolíticas y hemodinámicas 8489787018Tratado de odontología 1 1998-01-01 Smithkline Beecham, S.A. ][][Llibres{id=com.sigma.fs3.argos.domain.gpc.GpcLlibresPK[ifcactivitat=LLI, ifccomptador=123465],camposKey=8417046623Trombosis y hemostasia 1 2018-01-01 Arán Ediciones}, Llibres{id=com.sigma.fs3.argos.domain.gpc.GpcLlibresPK[ifcactivitat=LLI, ifccomptador=115314],camposKey=8469057812Hemofilia 1 2007-01-01 Real Academia de Cirugía y Medicina de Valladolid}][][][][][][][][][com.sigma.fs3.argos.domain.gpc.GpcTesis[id=com.sigma.fs3.argos.domain.gpc.GpcTesisPK[ifcactivitat=TES, ifccomptador=2145628801]]][][][][][][][][][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d801, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d715, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63eb5d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ec7a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dfc7, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e141, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e05f, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e060, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e265, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e4ea, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e95e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e42b, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ebb2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ea6d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e429, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d86d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d95e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d741, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d742, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63d759, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e42a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ea7e, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63ea8a, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@372c37, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dc2c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63df70, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dae2, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dad1, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e46c, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e2c8, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63e50d, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dfb4, com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@63dfb5][][][][][][][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4133af], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f6e0], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@413be7], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@41235d], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@4122e8], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@411db0]][][][][][][][]